NCT04571216View on ClinicalTrials.gov

Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

April 12, 2024

Study Completion Date

April 12, 2024

Conditions
Smoking CessationNicotine Dependence
Interventions
DRUG

NFL-101 dose 1

Subcutaneous injections

DRUG

NFL-101 dose 2

Subcutaneous injections

DRUG

Placebo

Subcutaneous injections

Trial Locations (9)

13015

Centre d'Investigation Clinique de Marseille Nord, Marseille

21079

CHU de Dijon, Dijon

33604

Centre d'Investigation Clinique de Bordeaux, Pessac

34295

Centre d'Investigation Clinique de Montpellier, Montpellier

35000

Centre d'Investigation Clinique de Rennes, Rennes

38610

Eurofins Optimed, Gières

56322

Groupe Hospitalier Bretagne Sud, Lorient

63003

Centre d'Investigation Clinique de Clermont-Ferrand, Clermont-Ferrand

86021

Centre d'Investigation Clinique de Poitiers (CIC 1402), Poitiers

Sponsors
All Listed Sponsors
lead

NFL Biosciences SAS

INDUSTRY

NCT04571216 - Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy | Biotech Hunter | Biotech Hunter